Akeso shares plunge 31.8% after FDA rejects ivonescimab application
Published 3 h ago2 sourcesEvidence: Reported
Johnson & Johnson is reportedly in talks to acquire Ollin Biosciences, an eye-disease biotech, for up to $3.4 billion. The deal would be the latest in a wave of biotech M&A, reflecting continued consolidation in the sector. Financial terms and final agreement remain unconfirmed.
AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works
Published 3 h ago2 sourcesEvidence: Reported
Published 15 h ago2 sourcesEvidence: Reported
Published 2 d ago2 sourcesEvidence: Reported
Published 3 d ago3 sourcesEvidence: Reported
Published 17 h ago2 sourcesEvidence: Reported
Published 2 d ago22 sourcesEvidence: Reported
Published 2 d ago1 sourceEvidence: Reported
Published 1 d ago1 sourceEvidence: Reported